We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Shoots Down Cornerstone’s Low-Sodium Drug
FDA Advisory Committee Shoots Down Cornerstone’s Low-Sodium Drug
September 21, 2012
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8–0 against recommending approval of Cornerstone Therapeutics’ lixivaptan to treat hypervolemic hyponatremia associated with heart failure.